Format

Send to

Choose Destination
Anticancer Res. 2014 Mar;34(3):1141-6.

The management of screen-detected breast cancer.

Author information

1
Department of Research Oncology, King's College London, Guy's Hospital Campus, Great Maze Pond, London SE1 9RT, U.K. michael.douek@kcl.ac.uk/muneer.ahmed@kcl.ac.uk.

Abstract

The increased use of mammography and introduction of breast screening programmes have resulted in a rise in clinically-occult breast cancer, with one-third of all breast carcinomata diagnosed being non-palpable. These types of cancer have a unique natural history and biology compared to symptomatic breast cancer and this needs to be taken into account when considering surgery and adjuvant treatment. The majority of studies demonstrating efficacy of adjuvant treatments are largely based on patients with symptomatic breast cancer. The current evidence for the role of surgery and adjuvant therapy for screen-detected breast cancer was reviewed in light of their improved prognosis, compared to symptomatic breast cancer.

KEYWORDS:

Adjuvant; adjuvant chemotherapy; adjuvant endocrine; adjuvant radiotherapy; breast cancer; review; screening

PMID:
24596351
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center